Adam Winstock
Professor of Addiction Medicine; Consultant Psychiatrist and Founder/Director of Global Drug Survey
Data updated
Research Footprint
Adam Winstock appears in 6 tracked papers (2013–2023), most studied alongside LSD, Psilocybin and DMT, across Substance Use Disorders (SUD), Set & Setting and Anxiety Disorders.
Most-cited paper: Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample (101 citations).
Frequent co-authors: Jason Ferris, James Rucker and Allan Young.
Background & Research
Adam Winstock is a London-based consultant psychiatrist and addiction medicine specialist who founded Global Drug Survey, an independent research organization focused on patterns of drug and alcohol use. His work spans psychedelics, MDMA, LSD, DMT, ayahuasca, and broader harm-reduction research, and he has published extensively on self-reported drug experiences and risks.
Key Impact
A leading figure in global survey-based research on psychedelics, club drugs, and substance use patterns, with widely cited work informing harm reduction and public health.
Collaboration Network
11 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Adam Winstock is associated with.
Global Drug Survey
Global anonymous survey platform with explicit psychedelic-use and microdosing self-report outputs in periodic reports.
View stakeholder →University College London
academicThe Understanding Neuroplasticity Induced by Tryptamines (UNITY) Project was launched at University College London. UNITY represents the first-in-human study of psychedelics at UCL. The team utilizes techniques such as fMRI, eye-tracking and experience sampling to enhance our understanding of the neurobiological mechanisms predicting cognitive and mental health outcomes following psychedelic use, initially investigating the effects of DMT.
View stakeholder →King's College London
academicThe Centre for Mental Health Research and Innovation and the Psychoactive Trials Group are actively conducting clinical trials with various psychedelic compounds to develop new care models for treatment-resistant depression, PTSD, and anorexia nervosa.
View stakeholder →